作为一种天然的IRAK4抑制剂,阿皮基宁可以缓解炎症
Pianchou Gongpan1, Tingting Xu2, Yufei Zhang3
1State Key Laboratory of Phytochemistry and Natural Medicines, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan 650201, China; CAS Key Laboratory of Tropical Plant Resources and Sustainable Use, Xishuangbanna Tropical Botanical Garden, Chinese Academy of Sciences, Kunming, Yunnan 650223, China.
概括
原蛋白 (Api) 是一种天然的IRAK4抑制剂,通过向关键信号通路来减少炎症. 这项研究揭示了Api.
科学领域:
- 免疫学和分子生物学
- 自然产品化学 自然产品化学
- 药物发现 药物发现 药物发现
背景情况:
- 失控的炎症导致许多疾病,使得像IRAK4这样的激酶成为关键的治疗点.
- 植物衍生化合物阿皮根因 (Api) 通过调节NF-κB和MAPK通路表现出抗炎性质,但其精确的机制尚不清楚.
研究的目的:
- 为了阐明apigenin (api) 的抗炎机制.
- 研究Api在调解急性炎症及其分子点中的特定作用.
主要方法:
- 建立了急性炎症和性结肠炎 (UC) 的小鼠模型,以评估Api的疗效.
- 使用转录组学 (RNA-seq),qPCR,西斑,ELISA,免疫光学和组织学进行验证.
- 通过生物化学测试 (激酶测试,SPR,CETSA) 和计算方法 (分子对接) 研究了Api与IRAK4的相互作用.
主要成果:
- 在急性和UC模型中,apigenin (Api) 显著降低了炎症.
- Api抑制了促炎性细胞因子和化学因子基因表达,并调节了巨细胞的免疫反应.
- 艾皮作为直接IRAK4抑制剂起作用,与激酶结合,并以IRAK4依赖的方式减少NF-κB和MAPK通路激活.
结论:
- 原蛋白 (Api) 被确定为一种新的,自然的IRAK4抑制剂,在转录层面抑制炎症信号.
- 这一发现为Api的抗炎作用提供了机理性的洞察力,并表明了基于Api的IRAK4抑制剂开发的潜力.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
161
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
161
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107
01:29Inflammatory Bowel Disease IV: Pharmacological Management
88
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
88
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
01:20The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K